Citations

Clear

813 citation(s) found for "He, Helen".

Updated Guidance on Use and Prioritization of Monoclonal Antibody Therapy for Treatment of COVID-19 in Adolescents
Wolf, Joshua , Abzug, Mark J., Anosike, Brenda I. , Vora, Surabhi B , Waghmare, Alpana , Sue, Paul K. , Olivero, Rosemary , Oliveira, Carlos R. , James, Scott H. , Morton, Ted , Marón, Gabriela , Schwenk, Hayden T. , Bio, Laura , Willis, Zachary , Lloyd, Elizabeth C , Hersh, Adam L. , Soma, Vijaya L, Ratner, Adam J. , Hayes, Molly , Grapentine, Steven P, Wattier, Rachel L , Lamb, Gabriella S , Zachariah, Philip , Nakamura, Mari , Schwenk, Hayden T , Huskins, Charles W, Ratner, Adam J , Downes, Kevin J , Zachariah, Philip , Waghmare, Alpana , Wolf, Joshua , Oliveira, Carlos R , Young, Jennifer L, Orscheln, Rachel C. , Huskins, W. Charles , Downes, Kevin J. , Chiotos, Kathleen

Mayo Clinic

Journal of the Pediatric Infectious Diseases Society | November 22, 2021 | Volume: 11 | Issue: 5 | Pages: 177-185

10.1093/jpids/piab124 | PMID 35107571 Get It

Abstract Background Starting in November 2020, the US Food and Drug Administration (FDA) has issued Emergency Use Authorizations (EUAs) for multiple novel virus-neutralizing monoclonal antibody therapies, including bamlanivimab monotherapy (now revoked), bamlanivimab and etesivimab, casirivimab and imdevimab (REGEN-COV), and sotrovimab, for treatment or postexposure prophylaxis of Coronavirus disease 2019 (COVID-19) in adolescents (≥12 years of age) and adults with certain high-risk conditions. Previous guidance is now updated based on new evidence and clinical experience. Methods A panel of experts in pediatric infectious diseases, pediatric infectious diseases pharmacotherapy, and pediatric critical care medicine from 18 geographically diverse US institutions was convened. Through a series of teleconferences and web-based surveys, a guidance statement was developed and refined based on a review of the best available evidence and expert opinion. Results The course of COVID-19 in children and adolescents is typically mild, though more severe disease is occasionally observed. Evidence supporting risk stratification is incomplete. Randomized controlled trials have demonstrated the benefit of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)-specific monoclonal antibody therapies in adults, but data on safety and efficacy in children or adolescents are limited. Potential harms associated with infusion reactions or anaphylaxis are reportedly low in adults. Conclusions Based on evidence available as of August 31, 2021, the panel suggests a risk-based approach to administration of SARS-CoV-2 monoclonal antibody therapy. Therapy is suggested for the treatment of mild to moderate COVID-19 in adolescents (≥12 years of age) at the highest risk of progression to hospitalization or severe disease. Therapeutic decision-making about those at moderate risk of severe disease should be individualized. Use as postexposure prophylaxis could be considered for those at the highest risk who have a high-risk exposure but are not yet diagnosed with COVID-19. Clinicians and health systems should ensure safe and timely implementation of these therapeutics that does not exacerbate existing healthcare disparities.
CTNI-53. RADIATION TREATMENT VOLUMES BEFORE AND AFTER BRAF/MEK THERAPY IN NEWLY DIAGNOSED PAPILLARY CRANIOPHARYNGIOMAS: A CORRELATIVE ANALYSIS OF THE ALLIANCE A071601 PHASE II TRIAL
Kabat, Brian, Twohy, Erin , Geyer, Susan M. , Vora, Shivangi, Gerstner, Elizabeth R. , Ruff, Michael W. , Reardon, David A. , Cohen, Adam L. , Bota, Daniela A. , Agarwalla, Pankaj K., Fuente, Macarena de la, Lesser, G. J., Campian, Jian , Kumthekar, Priya , Knopp, Michael, Barker, Fred G., Brown, Paul D. , Shih, Helen A. , Tabrizi, Shervin , Kaufmann, Timothy J. , Knopp, Michael V. , Cahill, Daniel P. , Santagata, Sandro , Galanis, Evanthia , Brastianos, Priscilla K.

Mayo Clinic

Neuro-Oncology | November 18, 2021 | Volume: 23 | Issue: Supplement_6 | Pages: vi72-vi72

10.1093/neuonc/noab196.278 Get It

Abstract PURPOSE Standard of care for craniopharyngiomas is surgery with or without radiotherapy (RT). Cohort A of Alliance A071601 evaluated the efficacy of BRAF/MEK inhibition with vemurafenib/cobimetinib in patients with previously untreated papillary craniopharyngiomas (PCP), which carry the BRAF V600E mutation. Cohort B is currently enrolling patients with recurrence after RT. In a correlative analysis, we examined changes in RT volumes after BRAF/MEK therapy in Cohort A. METHODS Previously unirradiated patients with BRAF-mutated PCP were treated with vemurafenib/cobimetinib. Sixteen patients had scans available before starting vemurafenib/cobimetinib (“pre-therapy”) and after completing therapy (“post-therapy”). Two patients went off study treatment after 8 and 9 days due to side-effects and were excluded for this analysis. Gross target volumes (GTV) were contoured on pre-therapy and post-therapy scans. On post-therapy scans, an additional target comprising gross disease and at-risk regions for microscopic residual disease (GTV-micro) was defined and considered the treatment volume. Clinical target volume (CTV) was a 5-mm uniform expansion on pre-therapy GTV and post-therapy GTV-micro. Volumes were independently reviewed by two radiation oncologists. Changes in volumes from pre- versus post-therapy were compared using the Wilcoxon signed rank test. RESULTS In 14 patients evaluated, 57% were female and median age at enrollment was 49.5 years (range 33-83). Median time on treatment was 8.9 months (range 4.0-18.0). Median GTV pre-therapy was 3.8 mL (range 0.2-23.4) versus 0.3 mL (range 0.0-3.2) post-therapy (p=0.0001) and 1.7 mL (range 0.1-8.0) post-therapy GTV-micro (p=0.0001). Median CTV pre-therapy was 13.7 mL (range 2.8-51.8) versus 9.1 mL (range 2.2-27.5) post-therapy (p=0.0001). All tumors abutted the optic chiasm pre-therapy, only 6 did post-therapy. CONCLUSIONS Vemurafenib/cobimetinib resulted in smaller RT volumes. BRAF/MEK inhibitors could reduce RT volumes and spare dose to surrounding normal structures. Enrollment to Cohort B of Alliance A071601 should be considered for patients with recurrent tumors after RT. SUPPORT https://acknowledgments.alliancefound.org
IMMU-18. GLIOBLASTOMA-DERIVED EXTRACELLULAR VESICLES INDUCE DRAMATIC CHANGES IN THE TRANSCRIPTOMIC LANDSCAPE OF MONOCYTES
Li, Helen , Jung, M. Katherine , Himes, Benjamin , Nesvick, Cody L. , Parney, Ian F.

Mayo Clinic

Neuro-Oncology | November 18, 2021 | Volume: 23 | Issue: Supplement_6 | Pages: vi95-vi95

10.1093/neuonc/noab196.377 Get It

Abstract Glioblastoma (GBM) is the most common and deadly primary brain tumor. Novel therapeutic strategies are urgently needed to improve outcomes, but a number of disease-specific barriers pose challenges to innovation. Tumor-mediated immunosuppression is one such hurdle, and a growing body of evidence suggests that GBM-derived extracellular vesicles (EVs) play an important role in host immunosuppression. GBM-derived EVs have been shown to induce the formation of immunosuppressive monocytes, including myeloid-derived suppressor cells. Work by our group and others has increasingly shown that these immunosuppressive monocytes are a heterogenous group, and that many constellations of surface markers are inadequate to capture the changes wrought by EVs. In order to better understand the effects of GBM-EVs on monocytes, we conducted RNA-seq analysis on monocytes collected from four healthy donors treated with GBM-derived EVs harvested by ultracentrifugation from the patient-derived BT116 cell line. Following 72h of EV conditioning, total RNA was harvested from treated monocytes and untreated controls. RNA-seq was performed using the Illumina HiSeq4000 platform with paired end index reads. Analysis was performed using RNA STAR and the hg19 ENCODE reference sequence. Differential expression analysis was performed using DESeq2. Genes with a false-discovery rate (FDR)-corrected P value < 0.05 and a log2 fold-change value of >|1| were considered significantly different between groups. Pathway analysis was performed using ClueGO in Cytoscape (GO term fusion on, p< 0.05). Unsupervised clustering analysis of the top 500 most differentially-expressed genes demonstrated grouping of BT116 EV-treated monocytes together versus untreated monocytes. Pathway analysis upregulated genes in pathways important for heparan sulfate proteoglycan synthesis and cholesterol synthesis, which could potentially point to positive regulation of EV uptake. Downregulated pathways included regulation of T cell differentiation and chemoattractant activity, underscoring the induction of a potentially immunosuppressive phenotype by GBM-derived EVs.
CTNI-13. MALIGNANT GLIOMA SUBSET FROM ACTUATE 1801 PHASE 1/2 STUDY OF 9-ING-41, A GLYCOGEN SYNTHASE KINASE 3 BETA (GSK-3β) INHIBITOR, AS A SINGLE AGENT AND COMBINED WITH CHEMOTHERAPY REFRACTORY
Safran, Howard , Powell, Steven , Carneiro, Benedito A. , Bastos, Bruno R. , Sahebjam, Solmaz , Odia, Yazmín , Cavalcante, Ludimila , Münster, Pamela N. , Wee, Wen , Giles, Francis Joseph

Mayo Clinic

Neuro-Oncology | November 18, 2021 | Volume: 23 | Issue: Supplement_6 | Pages: vi61-vi62

10.1093/neuonc/noab196.238 Get It

Abstract BACKGROUND GSK3β serine/threonine kinase regulates metabolism and glycogen biosynthesis. GSK3β overexpression promotes tumor progression and resistance through NF-κB and p53 apoptotic pathways. GSK3β inhibits immunomodulation by downregulating checkpoints, e.g. PD-L1 and LAG-3, and increasing NK and T-cell mediated tumor killing. 9-ING-41 is a small-molecule, potent, selective GSK3β inhibitor with preclinical activity. In chemoresistant PDX glioblastoma models, 9-ING-41 enhanced lomustine antitumor effect. METHODS Patients with refractory malignancies were treated with 9-ING-41 monotherapy (n=65) or combined with 8 cytotoxic regimens after prior exposure (n=162) in the first-in-human study (NCT03678883). The recurrent gliomas subset was treated with 9-ING-41 monotherapy IV TIW q21day cycles at 3.3, 5, 9.3, 15mg/kg, or combined with lomustine 30 mg/m² PO weekly q84day cycles. Primary objective was safety and tolerability. RESULTS An RP2D of 15mg/kg IV TIW was confirmed across all 9 regimens, no accentuation of chemotherapy toxicity noted. Of 18 glioma patients enrolled, 13 were glioblastoma, 2 anaplastic astrocytomas, 1 anaplastic oligodendroglioma, and 1 diffuse astrocytoma; 6 female, 12 male; median age 52 (30-69) years; median ECOG was 1 (0-2). All received initial radiation and temozolomide (18/18), prior salvage therapies included nitrosoureas (15/18), bevacizumab (8/18), TTFields (6/18), checkpoint inhibitor (4/18). Median recurrences 3 (1-6). NGS alterations included: IDH/wildtype (11), IDH/mutation(3); 1p19q/codeletion(10); MGMT/unmethylated(11), MGMT/methylated(1); EGFR/amplification(6), EGFR/v3mutation(3), TERT/mutation(6), PTEN/loss(3), NF1/rearrangement(2), ATRX/loss (2), TP53/mutation(4), CDKN2A/deletion(2), RB1/loss(1), PALB2/mutation(10). Four patients received 9-ING-41 monotherapy, 14 concurrently treated with lomustine. No SAEs or grade 3/4 AEs attributed to 9-ING-41 noted, only G1/2 vision changes (9/18, 50%), infusion reactions (4/18, 22%). Lomustine-related toxicities included G3/4 thrombocytopenia (3/14, 21%), and G1/2 fatigue (4/14, 28%). Median therapy duration was 55 (4-305); 1 partial response ( >50%) noted with 9-ING-41/lomustine. Median PFS and OS were 1.9 (0.3-11.1) and 6.0 (1.6-16.6) months, respectively. CONCLUSIONS 9-ING-41 plus/minus lomustine is safe and warrants further study in glioma patients.
Impact of Fenfluramine on the Expected SUDEP Incidence Rate in Patients with Dravet Syndrome
Pringsheim, M., Cross, J. Helen , Galer, B. S., Lagae, Lieven , Donner, Elizabeth , Gammaitoni, Arnold R. , Cross, Helen J , Gil‐Nagel, António , Devinsky, Orrin , Ceulemans, Berten , Schoonjans, An-Sofie , Wirrell, Elaine

Mayo Clinic

Neuropediatrics | November 17, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1055/s-0041-1739610 Get It

Empowering Women as Leaders in Pediatric Anesthesiology: Methodology, Lessons, and Early Outcomes of a National Initiative
Schwartz, Jamie McElrath , Markowitz, Scott D. , Yanofsky, Samuel D., Tackett, Sean , Berenstain, Laura K. , Schwartz, Lawrence , Flick, Randall P., Heitmiller, Eugenie S., Fiadjoe, John E. , Lee, Helen H. , Honkanen, Anita , Malviya, Shobha , Cladis, Franklyn P. , Lee, Jennifer K. , Flick, Randall, Deutsch, Nina

Mayo Clinic

Anesthesia & Analgesia | November 16, 2021 | Volume: 133 | Issue: 6 | Pages: 1497-1509

10.1213/ane.0000000000005740 | PMID 34517375 Get It

Research has shown that women have leadership ability equal to or better than that of their male counterparts, yet proportionally fewer women than men achieve leadership positions and promotion in medicine. The Women’s Empowerment and Leadership Initiative (WELI) was founded within the Society for Pediatric Anesthesia (SPA) in 2018 as a multidimensional program to help address the significant career development, leadership, and promotion gender gap between men and women in anesthesiology. Herein, we describe WELI’s development and implementation with an early assessment of effectiveness at 2 years. Members received an anonymous, voluntary survey by e-mail to assess whether they believed WELI was beneficial in several broad domains: career development, networking, project implementation and completion, goal setting, mentorship, well-being, and promotion and leadership. The response rate was 60.5% (92 of 152). The majority ranked several aspects of WELI to be very or extremely valuable, including the protégé-advisor dyads, workshops, nomination to join WELI, and virtual facilitated networking. For most members, WELI helped to improve optimism about their professional future. Most also reported that WELI somewhat or absolutely contributed to project improvement or completion, finding new collaborators, and obtaining invitations to be visiting speakers. Among those who applied for promotion or leadership positions, 51% found WELI to be somewhat or absolutely valuable to their application process, and 42% found the same in applying for leadership positions. Qualitative analysis of free-text survey responses identified 5 main themes: (1) feelings of empowerment and confidence, (2) acquisition of new skills in mentoring, coaching, career development, and project implementation, (3) clarification and focus on goal setting, (4) creating meaningful connections through networking, and (5) challenges from coronavirus disease 2019 (COVID-19) and the inability to sustain the advisor-protégé connection. We conclude that after 2 years, the WELI program has successfully supported career development for the majority of protégés and advisors. Continued assessment of whether WELI can meaningfully contribute to attainment of promotion and leadership positions will require study across a longer period. WELI could serve as a programmatic example to support women’s career development in other subspecialties.
Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19
Mahil, Satveer K. , Dand, Nick , Yiu, Zenas Z N , Zhang, Xian , Strangfeld, Anja , Mateus, Elsa F , Lawson‐Tovey, Saskia , Cuomo, Giovanna , Caprioli, Marta , Cruz-Machado, Ana Rita , Pereira, Ana Carolina Mazeda, Hasseli, Rebecca , Lorenz, Hanns‐Martin , Hoyer, Bimba F. , Trupin, Laura , Rush, Stephanie, Schmajuk, Gabriela , Jacobsohn, Lindsay, Seet, Andrea M. , Emadi, Samar Al, Wise, Leanna , Gilbert, Emily, Valenzuela-Almada, Maria O , Hsu, Tiffany , Sparks, Jeffrey A. , Xavier, Ricardo Machado , Flipo, René‐Marc , Cantagrel, A., Wallace, Zachary S. , Bhana, Suleman , Costello, Wendy, Grainger, Rebecca , Hausmann, Jonathan S. , Sufka, Paul , Machado, Pedro , Barker, Jonathan N., Smith, Catherine , Coker, Bola , Gisondi, Paolo, Jullien, D., Lambert, Jo, McAteer, Helen , Meynell, Freya, Moorhead, Lucy, Naldi, Luigi, Reynolds, Nick J. , Spuls, Phyllis, Vincent, Alexandra , Waweru, H, Reinisch, Walter , Rahier, Jean‐François , Lewis, James D. , Steinwurz, Flávio , Kissous-Hunt, Michele, Modesto, Irene , Konings, Marishka, Dahou, Brahim, Gómez, Gimena, Roberts, Karen , Báez, Roberto Miguel , Coello, Vanessa Viviana Castro , Salinas, María Jezabel Haye , Maldonado, F., Reyes, Alvaro A., Alle, Gelsomina , Tanten, Romina , Ficco, Hernán Maldonado , Tissera, Yohana , Pisoni, Cecilia , Paula, Alba, Albiero, Juan Alejandro, Schmid, María Marcela, Cosatti, Micaela , Gamba, María Julieta , Leandro, Carlevaris, Cusa, María Alejandra, Germán, Noelia, Bellomio, Verónica , Takashima, Lorena , Pera, Mariana , Elkin, M. S. Gálvez , Medina, María Alejandra , Savio, V. , Tessel, Romina Rojas, Alamino, Rodolfo Pérez, Werner, Marina Laura, Ornella, Sofía , Casalla, Luciana, Vega, María Celina De la , Severina, María de los Ángeles , Lucero, Luciana González , Romeo, Cecilia, Barbich, Tatiana, Baños, Andrea, Petruzzelli, Sandra, Matellan, Carla , Conti, Silvana, Lázaro, María Alicia, Gil, Gustavo Fabián Rodriguez, Risueño, Fabián, Quaglia, María Isabel, Scafati, Julia , Cuchiaro, Natalia Lili, Rebak, J., Pineda, Susana , Calvo, María Elena, Picco, Eugenia, Yanzi, Josefina Gallino , Maid, Pablo, Guaglianone, Debora, Morbiducci, Julieta Silvana , Porta, Sabrina , Herscovich, Natalia , Zamora, José Luis Velasco , Kisluk, Boris, Menescardi, Maria Sol Castaños, Gallo, Rosana, Maldini, Carla , Goizueta, Cecilia, Fernandez, Sabrina Solange de la Vega, Aeschlimann, Carolina, Subils, Gisela, Piette, Y, Devinck, Mieke , Maeyaert, Bea, Ribeiro, Francinne Machado , Ribeiro, Sandra Lúcia Euzébio , Trubert, Anne-Marie Chassin, Dong, Lingli , Cajas, Lui, Anić, Branimir, Čulo, Melanie-Ivana , Pavelic, Tea Ahel, Stranski, Kristina Kovacevic, Karanović, Boris , Píchová, Marta, Vassilopoulos, Dimitrios, Melgar, Gabriela Maria Guzman, Király, Márta , Vojdanian, Mahdi, Balbir‐Gurman, Alexandra , Abutiban, Fatemah , Buliņa, Inita , Bukauskienė, Loreta, Montiel, Beatriz E Zazueta, Ortiz, Angel Alejandro Castillo , Tehozol, Erick Adrian Zamora , Rosete, Diana Cervántes, Nares, Eduardo Martín, Reyna, Tatiana S Rodriguez, Gabayet, Marina Rull, Rodríguez, Deshiré Alpízar, Irazoque, Fedra, Jimenez, Xochitl, Bon, Lenny Geurts van, Zijlstra, T. R., Hoekstra, Monique , Adhoubi, Nasra Al , Salim, Babur , Giraldo, Enrique, Salinas, Ariel, Gil, Manuel Ugarte, Flood, Rachael , Felea, Ioana , Filipescu, Ileana, Rednic, Simona , Tamas, Maria Magdelena, Mlynáriková, Vanda , Skamlova, Martina, Žlnay, Martin, Mičeková, Dagmar, Cápová, L, Šteňová, Emὄke , Raffayová, Helena , Belakova, Gabriela, Straková, Eva , Senčarová, Marieta, Žlnayová, Soňa, Sabová, Anna, Spišáková, Daniela, Oetterová, Mária, Lukáčová, Oľga, Bakošová, Martina, Hočevar, Alojzija , Rubio, N. De la Torre , Sancho, Juan José Alegre , Coro, Montserrat Corteguera, García, Juan Carlos Cobeta , Martin, Maria Carmen Torres, Campos, José Luis Michi , Gómez‐Puerta, José A. , Yardimci, Gozd Kubra, İçaçan, Ozan Cemal , Çelik, Selda , Vasylets, Viktoriia, Vandevelde, Claire , Dunt, Sasha, Leeder, Jane, MacPhie, Elizabeth, Salerno, Rosaria, Graver, Christine, Williams, Katie, O’Reilly, Sheila, Devine, Kirsty, Tyler, Jennifer , Warner, Elizabeth, Pilcher, James, Patel, Samir J. , Nikiphorou, Elena , Chadwick, Laura , Jones, Caroline Mulvaney, Harrison, Beverley, Thornton, Lucy, O'Kane, Diana, Fusi, Lucia, Low, Audrey, Horton, Sarah , Jatwani, Shraddha , Baig, Sara , Bajwa, Hammad, Berglund, Vernon, Dahle, Angela, Dorman, Walter, Hargrove, Jody, Hilton, Maren, Lebedoff, Nicholas, Leonard, Susan, Pfeifer, Emily, Skemp, Archibald, Wolff, Anne , Cepeda, Eduardo, Todd, Derrick J. , Hare, Denise, Kilian, Adam, White, Douglas, Winter, Melanie, Fields, Theodore, Siegel, Caroline H. , Daver, Nicole, Harvey, Melissa , Kramer, Neil , Lamore, Concetta, Hogarty, Suneya, Yeter, Karen, Siddique, Faizah, Ban, Byung, Tanner, Tamar, Davis, William E. , Quinet, Robert, Scopelitis, Evangeline, Toribio, Karen Toribio, Detiege, Tameka Webb, Zakem, Jerald, Abbass, Khurram, Kepecs, Gilbert, Miranda, Lilliam, Guma, Michael, Haikal, Ammar, Mody, Sushama, Mueller, Daric, Zell, JoAnn, Dao, Kathryn H., Ezzati, Fatemeh, Parks, Deborah, Karp, David R. , Quiceno, Guillermo Andrés, Gilbert, Emily L , Sparks, Jeffrey A , Grainger, Rebecca , Hoyer, Bimba F , Wise, Leanna M , Lawson-Tovey, Saskia , Machado, Pedro M , Hausmann, Jonathan S , Hasseli, Rebecca , Xavier, Ricardo M , Hsu, Tiffany Y-T , Strangfeld, Anja , Mateus, Elsa F , Zamora Tehozol, Erick Adrian , Gomez-Puerta, Jose A , Izadi, Zara , Brenner, Erica J. , Yates, Mark , Ungaro, Ryan C. , Agrawal, Manasi , Colombel, Jean‐Frédéric , Gianfrancesco, Milena A , Hyrich, Kimme L , Carmona, Loreto , Klingberg, Eva , Mazeda, Carolina , Pfeil, Alexander , Katz, Patricia , Duarte‐García, Alí , Isnardi, Carolina A , Quintana, Rosana M , Soriano, Enrique Roberto , D'Silva, Kristin M , Patel, Naomi J , Marques, Cláudia Diniz Lopes , Kakehasi, Adriana María , Claudepierre, Pascal , Goupille, Philippe , Liew, Jean W. , Sirotich, Emily , Robinson, Philip C. , Griffiths, Christopher E.M. , Barker, Jonathan N., Yazdany, Jinoos , Kappelman, Michael D. , Bachelez, Hervé , Capon, Francesca , Cruz, Claudia de la , Mason, Kayleigh J. , Meglio, Paola Di , Gelfand, Joel M. , Gisondi, Paolo , Iversen, Lars , Langan, Sinéad , Puig, L. , Torres, Tiago , Tsakok, Teresa , Warren, Richard Bruce , Ng, Siew C. , Gearry, Richard B. , Reinisch, Walter , Lewis, James D , Kaplan, Gilaad G. , Maldonado, Federico N, Nieto, Romina , Gobbi, Carla Andrea , Cogo, Karina, García, Mercedes , Moyano, Sebastián , Bertoli, Ana María , Martiré, María Victoria , Rath, Eva, Piette, Yves, Pinheiro, Marcelo M. , Ibañez, Sebastián , Barešić, Marko , Vencovský, Jiří , Filková, Mária , Hamoud, Hesham Salah , So, Ho , Zepa, Jūlija , Vega‐Morales, David , Reyna, Tatiana Sofía Rodríguez, Nowakowski, Jarosław , Conway, Richard , McCarthy, Géraldine , Filipescu, I., Groseanu, Laura , Macejová, Želmíra , Strakova, Eva, Campos, Jose, Akar, Servet , Yeoh, Su‐Ann , Morgan, Jennifer , Wilson, Jeffrey, Wolff, Anne, Hare, Denise, Calabrese, Cassandra M. , Adams, Christopher, Khosroshahi, Arezou , Ruderman, Eric , Jayatilleke, Arundathi , Bays, Alison , Parks, Deborah

Mayo Clinic

JAMA Network Open | October 20, 2021 | Volume: 4 | Issue: 10 | Pages: e2129639

10.1001/jamanetworkopen.2021.29639 | PMID 34661663 Get It

Phase III Trial Adding Vincristine-Topotecan-Cyclophosphamide to the Initial Treatment of Patients With Nonmetastatic Ewing Sarcoma: A Children's Oncology Group Report
Leavey, Patrick J. , Laack, Nadia N. , Krailo, Mark D., Buxton, Allen, Randall, R. Lor , DuBois, Steven G. , Reed, Damon R. , Grier, Holcombe E., Hawkins, Douglas S. , Pawel, Bruce, Nadel, Helen , Womer, Richard B. , Letson, G. Douglas, Bernstein, Mark, Brown, Kenneth, Maciej, Alexis, Chuba, Paul, Ahmed, Atif A., Indelicato, Daniel J. , Wang, Dian, Marina, Neyssa , Janeway, Katherine A. , Mascarenhas, Leo , Gorlick, Richard , Janeway, Katherine A , Mascarenhas, Leo , Laack, Nadia N Issa , Hawkins, Douglas S , Reed, Damon R , Randall, Robert Lor , Indelicato, Daniel J , Leavey, Patrick , Krailo, Mark D., Buxton, Allen, DuBois, Steven G , Grier, Holcombe E., Pawel, Bruce, Nadel, Helen , Womer, Richard , Letson, G. Douglas, Bernstein, Mark, Brown, Kenneth, Maciej, Alexis, Chuba, Paul, Ahmed, Atif A., Wang, Dian, Marina, Neyssa

Mayo Clinic

Journal of Clinical Oncology | October 15, 2021 | Volume: 39 | Issue: 36 | Pages: 4029-4038

10.1200/jco.21.00358 | PMID 34652968 Get It

PURPOSE The primary aim of this phase III randomized trial was to test whether the addition of vincristine, topotecan, and cyclophosphamide (VTC) to interval compressed chemotherapy improved survival outcomes for patients with previously untreated nonmetastatic Ewing sarcoma. METHODS Patients were randomly assigned to receive standard five-drug interval compressed chemotherapy (regimen A) for 17 cycles or experimental therapy with five cycles of VTC within the 17 cycles (regimen B). Patients were stratified by age at diagnosis (< 18 years and ≥18 years) and tumor site (pelvic bone, nonpelvic bone, and extraosseous). Tumor volume at diagnosis was categorized as < 200 mL or ≥ 200 mL. Local control occurred following six cycles. Histologic response was categorized as no viable or any viable tumor. Event-free survival (EFS) and overall survival (OS) were compared between randomized groups with stratified log-rank tests. RESULTS Of 642 enrolled patients, 309 eligible patients received standard and 320 received experimental therapy. The 5-year EFS and OS were 78% and 87%, respectively. There was no difference in survival outcomes between randomized groups (5-year EFS regimen A v regimen B, 78% v 79%; P = .192; 5-year OS 86% v 88%; P = .159). Age and primary site did not affect the risk of an EFS event. However, age ≥ 18 years was associated with an increased risk of death at 5 years (hazard ratio 1.84; 95% CI, 1.15 to 2.96; P = .009). The 5-year EFS rates for patients with pelvic, nonpelvic bone, and extraosseous primary tumors were 75%, 78%, and 85%, respectively. Tumor volume ≥ 200 mL was significantly associated with lower EFS. CONCLUSION While VTC added to five-drug interval compressed chemotherapy did not improve survival, these outcomes represent the best survival estimates to date for patients with previously untreated nonmetastatic Ewing sarcoma.
First- and Third-Trimester Urinary Phthalate Metabolites in the Development of Hypertensive Diseases of Pregnancy
Bedell, Sabrina , Lyden, Grace R. , Sathyanarayana, Sheela , Barrett, Emily S. , Ferguson, Kelly K. , Santilli, Ashley R. , Bush, Nicole R. , Nguyen, Ruby H.N. , Bedell, Sabrina M , Nguyen, Ruby H N , Swan, Shanna Helen , McElrath, Thomas Frederick

Mayo Clinic

International Journal of Environmental Research and Public Health | October 11, 2021 | Volume: 18 | Issue: 20 | Pages: 10627

10.3390/ijerph182010627 | PMID 34682373 Get It

The purpose of this study was to determine whether maternal urinary phthalate metabolite concentrations are associated with the development of higher blood pressure or pregnancy-induced hypertension (PIH). Participants were women without chronic hypertension who enrolled in The Infant Development and the Environment Study, a prospective pregnancy cohort conducted at four U.S. academic medical centers from 2010–2012. Prenatal records were reviewed to obtain blood pressure measurements and diagnoses of PIH (gestational hypertension, preeclampsia, eclampsia, and HELLP syndrome, defined as hemolysis, elevated liver enzymes, and low platelet count). Complete-case analyses used multivariable linear and logistic regression for analysis of blood pressure measurements and PIH diagnoses, respectively. In the final dataset (N = 668), higher concentrations of first-trimester monoethyl phthalate (MEP) and mono-3-carboxypropyl phthalate (MCPP) and third-trimester mono-isobutyl phthalate (MiBP) were significantly associated with a medical chart diagnosis of PIH. First-trimester mono-n-butyl phthalate (MBP) and MEP along with the sum of di-(2-ethylhexyl) phthalate metabolites (∑DEHP) were each associated with increased systolic blood pressure across pregnancy. In conclusion, several phthalate metabolite concentrations were significantly associated with PIH and greater increases in systolic blood pressure across pregnancy.
Genome-Wide Association Study of Peripheral Artery Disease
Zuydam, Natalie R. van , Stiby, Alexander, Abdalla, Moustafa , Austin, Erin , McLachlan, Stela , Vlachopoulou, Efthymia, Ahlqvist, Emma , Liao, Chen Di , Sandholm, Niina , Robertson, Neil R., Rayner, Nigel W. , Lindholm, Eero , Sinisalo, Juha , Kallio, Milla , Weiss, Emily , Price, Jackie F. , Paterson, Andrew D. , Klein, Barbara E.K. , Palmer, Colin N.A. , Groop, Per‐Henrik , Groop, Leif , Morris, Andrew P. , Hopewell, Jemma C. , Colhoun, Helen M. , Grétarsdóttir, Sólveig , Þorsteinsdóttir, Unnur , Stefánsson, Kāri , Michael, Mark , Kanninen, Timo, Patrono, Carlo, Nuutila, Pirjo , McKeague, Paul, Steckel-Hamann, Birgit, Gan, Li‐Ming , Nogoceke, Everson, Jablonka, Bernd, Brosnan, Mary-Julia, van Zuydam, Natalie R , Ahlqvist, Emma , Di Liao, Chen , Sandholm, Niina , Forsblom, Carol , Rayner, N William , Lindholm, Eero , Sinisalo, Juha , Perola, Markus , Kallio, Milla , Weiss, Emily , Paterson, Andrew , Salomaa, Veikko , Palmer, Colin N A , McCarthy, Mark I , de Andrade, Mariza , Hopewell, Jemma C , Colhoun, Helen M , Kullo, Iftikhar J , Dahlström, Emma H. , Mahajan, Anubha , McCarthy, Mark I. , Andrade, Mariza de , Kullo, Iftikhar J. , Þorleifsson, Guðmar , Mark, Michael, Thorand, Barbara , Remuzzi, Giuseppe , Dunger, David B. , Shore, Angela C. , Smith, Ulf , Ylä-Herttuala, Seppo , Cobelli, Claudio , Bellazzi, Riccardo , Ferrannini, Ele , Patrono, Carlo, Tortoli, Piero

Mayo Clinic

Circulation: Genomic and Precision Medicine | October 4, 2021 | Volume: 14 | Issue: 5 | Pages: No page available

10.1161/circgen.119.002862 | PMID 34601942 Get It

Background: Peripheral artery disease (PAD) affects >200 million people worldwide and is associated with high mortality and morbidity. We sought to identify genomic variants associated with PAD overall and in the contexts of diabetes and smoking status. Methods: We identified genetic variants associated with PAD and then meta-analyzed with published summary statistics from the Million Veterans Program and UK Biobank to replicate their findings. Next, we ran stratified genome-wide association analysis in ever smokers, never smokers, individuals with diabetes, and individuals with no history of diabetes and corresponding interaction analyses, to identify variants that modify the risk of PAD by diabetic or smoking status. Results: We identified 5 genome-wide significant ( P association ≤5×10 −8 ) associations with PAD in 449 548 (N cases =12 086) individuals of European ancestry near LPA (lipoprotein [a]), CDKN2BAS1 (CDKN2B antisense RNA 1), SH2B3 (SH2B adaptor protein 3) - PTPN11 (protein tyrosine phosphatase non-receptor type 11), HDAC9 (histone deacetylase 9), and CHRNA3 (cholinergic receptor nicotinic alpha 3 subunit ) loci (which overlapped previously reported associations). Meta-analysis with variants previously associated with PAD showed that 18 of 19 published variants remained genome-wide significant. In individuals with diabetes, rs116405693 at the CCSER1 (coiled-coil serine rich protein 1 ) locus was associated with PAD (odds ratio [95% CI], 1.51 [1.32–1.74], P diabetes =2.5×10 −9 , P interactionwithdiabetes =5.3×10 −7 ). Furthermore, in smokers, rs12910984 at the CHRNA3 locus was associated with PAD (odds ratio [95% CI], 1.15 [1.11–1.19], P smokers =9.3×10 −10 , P interactionwithsmoking =3.9×10 −5 ). Conclusions: Our analyses confirm the published genetic associations with PAD and identify novel variants that may influence susceptibility to PAD in the context of diabetes or smoking status.